Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Yoshikazu Takahashi, Hidekazu Shirota, Takashi Yoshioka, Takuhiro Yamaguchi, Kota Ouchi, Michio Kuroki, Shin Takahashi, Masahiro Takahashi, Masaki Tanaka, Masanobu Takahashi, Chikashi Ishioka, Yasuhiro Sakamoto, Hideki Shimodaira, Hiroo Imai, Satoshi Kato, Keigo Komine, Kazunori Otsuka, Hiroyuki Shibata, Hisatsugu Ohori, Hiroaki Yamaguchi, Yasushi Tsuji
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods This single-arm, open-label, multicenter, phase II study included elderly patients aged 65 years or more
Autor:
Monserrat Mangas, Flora López, Marc Diez, Juana María Cano, Alberto Carmona-Bayonas, Alfonso Martín Carnicero, Aitziber Gil-Negrete, Manuel Cánovas, Marcelo Garrido, Paula Cerdá, Paola Pimentel, Alicia Hurtado, Marta Martín Richard, Federico Longo, Carolina Hernández Pérez, Ana Montes, Rosario Vidal Tocino, Eva Martínez de Castro, Aranzazu Arias-Martinez, Javier Gallego, Mónica Granja, Laura Visa, Nieves Martinez Lago, Carles Pericay Pijaume, Natalia Castro Unanua, Avinash Ramchandani, Raquel Hernández, Ana Custodio, Tamara Sauri, Paula Jiménez-Fonseca, Gema Aguado, María Luisa Limón, Mariona Calvo, Aitor Azkarate
Publikováno v:
Scientia
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Background The purpose of our study was to develop an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer (AGC), and to assess the external validity of docetaxel trials in individual patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82837869875d5aad20b11f5093a89906
https://hdl.handle.net/11351/7737
https://hdl.handle.net/11351/7737
Autor:
Martin J. van den Bent, Katerina Bakunina, Jacoline E C Bromberg, Linda Dirven, Samar Issa, Jeanette K. Doorduijn, Matthijs van der Meulen
Publikováno v:
Journal of Neuro-Oncology, 152(2), 357-362. Kluwer Academic
Journal of Neuro-Oncology, 152(2), 357-362. SPRINGER
Journal of Neuro-Oncology
Journal of Neuro-Oncology, 152(2), 357-362. SPRINGER
Journal of Neuro-Oncology
Introduction To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. Methods In the HOVON 105/ ALLG NHL 24 phase III study patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a7bd8dbbae5896422024956ad26b38f
https://hdl.handle.net/1887/3251117
https://hdl.handle.net/1887/3251117
Autor:
Ana Custodio, Carolina Hernández Pérez, Mónica Granja, Aitor Azkarate, Aitziber Gil-Negrete, Laura Visa, Manuel Cánovas, Carles Pericay Pijaume, Tamara Sauri, Patricia Morales del Burgo, Gema Aguado, Felipe Alvarez-Manceñido, Olbia Serra, Paula Jiménez-Fonseca, Nieves Martinez Lago, M. Luisa Limon, Maria Alsina, Alicia Hurtado, Aranzazu Arias-Martinez, Alfonso Martín Carnicero, Javier Gallego, Ana Montes, P. Reguera, Paola Pimentel, Juana María Cano, Rosario Vidal Tocino, Virginia Arrazubi, Alberto Carmona-Bayonas, Diego Cacho Lavin, Alba Martinez-Torron, Avinash Ramchandani, Marta Martín Richard, Raquel Hernández, Flora López
Publikováno v:
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
Background Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb6610ee161c1b474b11a4778f667108
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4917
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4917
Autor:
Gessica Abate, Nadia Bulzonetti, Erika Moscarelli, Francesca De Felice, Daniela Musio, Vincenzo Tombolini
To evaluate treatment outcomes after definitive chemoradiotherapy (CRT) for human papilloma virus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC). We analyzed data concerning HPV-negative OPSCC patients treated with curative intent. All
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bfc73d5dc8420ba6b2ec27f48151047
http://hdl.handle.net/11573/1360016
http://hdl.handle.net/11573/1360016
Autor:
Andrés Cervantes, Hans Wildiers, Michael C. Wei, Mafalda Oliveira, Carlos Becerra, Cristina Saura, John Bond, Heather M. Moore, Stephen Lane Richey, Todd M. Bauer, Ian E. Krop, Timothy R. Wilson, Philippe L. Bedard, Manish R. Patel, Vandana G Abramson, Na Cui, Eric Reyner
PURPOSE: This open-label, phase Ib, dose-escalation, and dose-expansion study (NCT01862081) evaluated taselisib with a taxane in locally advanced or metastatic breast cancer (BC) and/or non-small cell lung cancer (NSCLC). METHODS: Patients received t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f39f99cf25167457215cd64d3bc8206
https://lirias.kuleuven.be/handle/123456789/640324
https://lirias.kuleuven.be/handle/123456789/640324
Autor:
Mitsuro Kanda, Shinji Fujieda, Koji Oba, Kenta Murotani, Tomomi Kashiwada, Yoshitaka Morita, Hideyuki Mishima, Ken Nakata, Ho Min Kim, Chu Matsuda, Junichi Sakamoto, Tadamichi Denda
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78(6):1253-1261
Purpose: Dose adjustment of 5-fluorouracil (FU) based on pharmacokinetic monitoring has been shown to reduce toxicities and increase efficacy compared with dosing based on body surface area in patients with metastatic colorectal cancer (mCRC). We eva
Autor:
Manuel Haschke, Christoph Driessen, Florian Strasser, Thomas Wälti, Beat Thürlimann, Markus Joerger, Alexander von Kameke, Holger Barth, Alexander Hoemme, Claudia Lehner, Stephan Krähenbühl, Martin Früh
Publikováno v:
Hoemme, Alexander; Barth, Holger; Haschke, Manuel Martin; Krähenbühl, Stephan; Strasser, Florian; Lehner, Claudia; von Kameke, Alexander; Wälti, Thomas; Thürlimann, Beat; Früh, Martin; Driessen, Christoph; Joerger, Markus (2019). Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer chemotherapy and pharmacology, 83(4), pp. 763-774. Springer 10.1007/s00280-019-03783-9
The risk of potential drug-drug interactions (PDI) is poorly studied in oncology. We included 105 patients with advanced non-small-cell lung cancer (NSCLC), 100 patients with advanced breast cancer (BC) and 100 patients of the palliative care unit (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f309b7bad29964e6950f6e4be5b646d9
Autor:
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J, AGAMENON study group
Publikováno v:
Gastric Cancer
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f3d92d4953160cc76bd58c743d53ed
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7086
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7086
Autor:
Christophe Le Tourneau, Karen Small, Marie Paule Sablin, Marco Gobbi, Da Zhang, Cyrine Ezzili, Claire Fabre, Honghong Zhou, Ellie Im, Nabeegha Shinwari, Mustapha Zoubir
Dinaciclib is a novel selective inhibitor of cyclin-dependent kinase (CDK)1, CDK2, CDK5, and CDK9. We conducted a phase I study to investigate the effects of dinaciclib when administered with rituximab. In this phase I nonrandomized dose-escalation 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d4813beda403d9d13d1afb926f5240
http://hdl.handle.net/11567/783410
http://hdl.handle.net/11567/783410